Trials / Completed
CompletedNCT07044401
A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices
A Phase 1, Randomized, Open-label, Single-Dose, Crossover Study to Investigate the Effect of Injection Site on Relative Bioavailability of KAI-9531 Subcutaneous Injection in Participants With a Range of Body Mass Indices
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Kailera · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objective of the study is to assess the relative bioavailability of KAI-9531 subcutaneous (SC) injection in the upper arm and thigh compared to the abdomen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KAI-9531 | SC Injection. |
Timeline
- Start date
- 2025-07-14
- Primary completion
- 2025-11-13
- Completion
- 2025-11-13
- First posted
- 2025-07-01
- Last updated
- 2025-12-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07044401. Inclusion in this directory is not an endorsement.